Nerve-sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy
|
|
- Gerard Small
- 5 years ago
- Views:
Transcription
1 Blackwell Science, LtdOxford, UK IJU International Journal of Urology Blackwell Science Asia Pty Ltd 910October Postchemotherapy nerve-sparing RPLND N Nonomura et al /j x Original Article539544BEES SGML International Journal of Urology (2002) 9, Original Article Nerve-sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy NORIO NONOMURA, 1 KAZUO NISHIMURA, 1 NATSUKI TAKAHA, 1 HITOSHI INOUE, 1 TAKESHI NOMOTO, 2 YOUICHI MIZUTANI, 2 MASAHIRO NAKAO, 2 AKIHIKO OKUYAMA 1 AND TSUNEHARU MIKI 2 1 Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and 2 Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan Abstract Key words Background: Nerve-sparing techniques are commonly used in retroperitoneal lymph node dissection (RPLND) in patients with early stage testicular germ cell tumors to preserve postoperative ejaculation. The indications for nerve-sparing procedures have been extended to patients who have residual retroperitoneal tumor postchemotherapy with an increase in the incidence of local recurrence. Here, we report on 26 Japanese men with advanced testicular cancer who underwent nerve-sparing RPLND after partially successful chemotherapy. Methods: Between January 1995 and December 2000, 26 patients with metastatic or recurrent testicular cancer underwent nerve-sparing RPLND after chemotherapy. Eight patients had seminoma and 18 had non-seminoma. Three patients received high-dose chemotherapy with carboplatin (250 mg/m 2 per day 5 days), etoposide (300 mg/m 2 per day 5 days) and ifosfamide (1.5 g/m 2 per day 5 days) in combination with peripheral blood stem cell transplantation. Results: In all cases, lumbar splanchnic nerves were preserved macroscopically during the operation, at least unilaterally. Twenty-two patients (84.6%) achieved antegrade ejaculation during a mean follow-up at 3.9 months (range: 1 7 months). Three patients have fathered children. Only one patient suffered a retroperitoneal recurrence during a median follow-up at 25.8 months (range: 6 76 months). Conclusion: Nerve-sparing procedures for RPLND are appropriate for patients with metastatic testicular cancer, even after chemotherapy. The procedure preserves ejaculatory function in the majority of the patients without increasing the risk of local recurrence. Nerve-sparing RPLND improves the quality of life in patients who require postchemotherapy RPLND to treat residual tumor. chemotherapy, germ cell tumor, nerve-sparing retroperitoneal lymph node dissection, testicular cancer. Introduction Conventional bilateral retroperitoneal lymph node dissection (RPLND) for testicular tumors results in permanent loss of seminal emission and ejaculation in a Correspondence: Norio Nonomura MD PHD, Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita , Japan. nono@uro.med.osaka-u.ac.jp Received 5 December 2001; accepted 8 April majority of patients. 1 3 Anatomical studies have shown that the lumbar splanchnic nerves that form the superior hypogastric plexus at the aortic bifurcation are essential for normal ejaculation. 4,5 These anatomical studies led to attempts to preserve normal ejaculation in patients with early stage testicular germ cell tumors without increasing the incidence of retroperitoneal recurrence by modifying the dissection template. 4,6 Most patients with a residual retroperitoneal mass after chemotherapy have impaired ejaculatory function because standard RPLND had been performed, rather than nerve-sparing RPLND. 3,7 However, based on the
2 540 N Nonomura et al. success of nerve-sparing procedures in patients with early stage testicular tumors, the group at Indiana University performed nerve-sparing RPLND in selected patients with relatively small residual retroperitoneal tumors after chemotherapy. 8 Based on their successful results, the indications for nerve-sparing dissection in postchemotherapy patients have been expanded without any increase in the rate of local recurrence. 9,10 Nervesparing procedures can improve the quality of life in patients who must undergo RPLND. Here, we report the clinical results of nerve-sparing RPLND in 26 Japanese men with residual retroperitoneal tumor after chemotherapy for metastatic or recurrent testicular germ cell tumors, and assessed their ejaculatory function and the outcome of cancer control in the relatively short-term. Methods Patients Between January 1995 and December 2000, 26 patients underwent nerve-sparing RPLND for residual retroperitoneal tumor after chemotherapy. Demographics, clinical characteristics, pathologic findings, and chemotherapy regimens are summarized in Table 1. Staging was done according to the General Rules for Clinical and Pathological Studies on Testicular Tumors (Second edition). 11 Eight patients had a seminoma, and the other 18 had non-seminoma. Before the operation, all the patients were informed that we do not have our own long-term results of this procedure in terms of cancer control. Written informed consent was obtained before the operation from all 26 patients who requested nervesparing RPLND. Chemotherapy Three patients received high-dose chemotherapy with carboplatin (250 mg/m 2 per day 5 days), etoposide (300 mg/m 2 per day 5 days), and ifosfamide (1.5 g/m 2 per day 5 days) in combination using peripheral blood stem cell transplantation. One of these patients developed a recurrence of his seminoma after primary chemotherapy and nerve-sparing RPLND. In this case, infra-renal-hilar paracaval lymph node metastasis was identified 6 months after radical orchiectomy. The patients underwent limited right-sided (nerve-sparing) RPLND with the modified template 6 after three courses of chemotherapy (BEP: bleomycin, etoposide, and cisplatinum). Six months after RPLND, right hydronephrosis developed due to obstruction by enlarged paracaval and interaortocaval lymph nodes. The patient underwent two courses of BEP, two courses of VIP (etoposide, ifosfamide, and cisplatinum), two courses of high-dose chemotherapy and then received 40 Gy of radiation. After that, we performed full bilateral nerve-sparing RPLND. In some of the patients, serum tumor markers such as alpha-fetoprotein (AFP), b-subunit of human chorionic gonadotropin (bhcg) and/or lactate dehydrogenase (LDH) were elevated. All of these serum tumor markers have been normalized during the chemotherapy. After chemotherapy, they stayed normal levels for at least 4 weeks until RPLND. Nerve-sparing retroperitoneal lymph node dissection All patients underwent complete bilateral RPLND through a midline transperitoneal incision. The posterior peritoneal incision was made through the mesenteric root from the cecum to the ligament of Treitz. Selfretaining retractors provided good exposure of the paracaval, interaortocaval, and paraaortal zones. The lymphatic tissue was incised over the anterior surface of the aorta and the vena cava. The precaval incision was extended from the origin of the renal veins to the confluence of the internal iliac veins, and the preaortic from the left renal vein to the inferior mesenteric artery. Lymphatic tissue was then rolled medially and laterally off the vena cava and the aorta. The superior hypogastric plexus was identified and preserved at the bifurcation of the aorta. On the right side, the branches of the right lumbar splanchnic nerves leading to the superior hypogastric plexus were identified underneath the inferior vena cava during the split and roll procedures. On the left side, the sympathetic trunks and the lumbar splanchnic nerves were identified dorsolaterally to the aorta. Then, the fibers from L2, L3, and L4 were dissected distally. Results Perioperative data The mean time of operation (including the time for resection of lung or liver metastases) was 636 min (range: ), and the mean intraoperative blood loss was 1037 g (range: g). No patient suffered a major complication (Table 2). Pathology of the surgical specimen Of the 10 patients with pulmonary metastases, six achieved complete remission with systemic chemo-
3 Postchemotherapy nerve-sparing RPLND 541 Table 1 Characteristics of 26 patients who underwent nerve-sparing retroperitoneal lymph node dissection (RPLND) Case no. Age Site Pathology Tumor marker Stage Metastatic sites Chemotherapy before RPLND 1 24 Rt E + T AFP + bhcg + LDH I RPLN BEP(1)ÆVIP(4) 2 37 Rt S LDH I RPLN BEP(3)ÆRPLNDÆBEP(2)ÆVIP(2)ÆHDCÆRT 3 24 Lt S bhcg IIA RPLN PVB(3) 4 34 Lt S + E AFP + bhcg IIA RPLN BEP(4) 5 35 Lt S+ E AFP IIA RPLN BEP(3) 6 18 Lt S + E AFP + bhcg IIB RPLN BEP(4)ÆCPT-ND(7)ÆTIP(4) 7 21 Rt S bhcg IIB RPLN BEP(3) 8 29 Lt S+ E + T AFP + bhcg + LDH IIB RPLN BEP(2)ÆEP(2) 9 31 Rt S bhcg + LDH IIB RPLN BEP(3)ÆVIP(1)ÆBEP(1)ÆVIP(1) Rt S + E + IT AFP + bhcg + LDH IIB RPLN BEP(3)ÆEP(1) Rt S + Y LDH IIB RPLN BEP(4) Rt S LDH IIB RPLN BEP(5) Lt S IIB RPLN BEP(3)ÆEP(2) Lt S LDH IIB RPLN BEP(5) Lt S IIB RPLN BEP(3)ÆEP(1) Lt S + C LDH IIIA RPLN + Mediastinal LN BEP(5) Rt Y + C AFP IIIB1 RPLN + Lung VIP(4) Lt E + Y AFP + bhcg IIIB2 RPLN + Lung BEP(3)ÆHDC Lt E + T AFP + LDH IIIB2 RPLN + Lung BEP(3)ÆVIP(2) Lt E AFP + bhcg + LDH IIIB2 RPLN + Lung BEP(3)ÆEP(1) Lt E AFP + bhcg + LDH IIIB2 RPLN + Lung VIP(5) Lt S + E AFP + bhcg + LDH IIIB2 RPLN + Lung BEP(5) Rt S + E bhcg IIIB2 RPLN + Lung BEP(3) Rt E + T AFP IIIB2 RPLN + Lung BEP(3) Lt E + T AFP + LDH IIIC RPLN + Lung + Liver BEP(5) Rt E + T AFP + LDH IIIC RPLN + Lung + Liver BEP(4)ÆVIP(4)ÆHDC C, choriocarcinoma; E, embryonal carcinoma; IT, immature teratoma; S, seminoma; T, teratoma; Y, yolk sac tumor. AFP, alpha-fetoprotein; bhcg, b-subunit of human chorionic gonadotropin; LDH, lactate dehydrogenase. retroperitoneal lymph node structure. BEP, bleomycin + etoposide + cisplatinum; CPT-ND, cisplatinum S; EP, etoposide + cisplatinum; HDC, high-dose chemotherapy; PVB, cisplatinum + vinblastin + bleomycin; RT, radiotherapy; TIP, paclitaxel + ifosfamide S; VIP, etoposide + ifosfamide + cisplatinum.
4 542 N Nonomura et al. Table 2 Demographics, clinical characteristics and outcome of nerve-sparing retroperitoneal lymph node dissection (RPLND) Case no. Operation time (min) Blood loss during operation (ml) Spared lumbar roots (months after RPLND) Ejaculation recovery Pathology of surgical specimen Outcome Follow-up (months) Bil. L2-3 Yes (1) T (growing NED 23 teratoma) Lt. L2-4 Yes (7) N/F NED Rt. L2-4, Lt. L3 Yes (2) N/F NED Bil. L2-3 Yes (5) T NED Rt. L2-3 Yes (3) T NED Rt. L2-3, Lt. L3 Yes (2) T NED Bil. L2-4 Yes (7) N/F NED Rt. L2-3 Yes (4) Residual cancer NED Rt. L3-3, Lt. L2-4 Yes (2.5) N/F NED Rt. L2-3 Yes (1) T NED Bil. L2-3 No (4) N/F NED Rt. L2-3 Yes (6) N/F NED Bil. L2-4 Yes (7) N/F NED Bil. L2-3 No (5) N/F NED Rt. L2-4 No (24) N/F NED Bil. L2-3 Yes (1) N/F NED Bil. L2-3 Yes (3) T NED Rt. L2-3 No (27) IT NED Rt. L2-3 Yes (6) N/F NED Lt. L2-3 Yes (1) N/F NED Rt. L2-3 Yes (6) N/F NED Rt. L2-3 Yes (1) Residual cancer AWT 8 (recurred at 6 months) Rt. L2-3 Yes (1) N/F NED Rt. L3 Yes (7) T NED Rt. L2-3 Yes (6) T (growing NED 13 teratoma) Bil. L2-4 Yes (1) T NED 37 Time of operation included resection of lung or liver metastases. AWT, alive with tumor; IT, immature teratoma; NED, no evidence of disease; N/F, necrotic fibrotic tissue; RPLND, retroperitoneal lymph node dissection; T, teratoma. therapy. However, none of the primary tumors contained teratoma elements. The remaining four patients (cases 19 and 24 26) underwent resection of residual pulmonary metastasis concurrent with RPLND. In two patients with stage 3C disease, resection of the liver metastases was also performed concomitantly with RPLND. None of the surgical specimens of lung or liver contained viable cancer cells. Fourteen retroperitoneal specimens showed necrotic fibrotic tissue, nine contained mature teratoma, and one contained immature teratoma (case 18). Viable cancer cells were seen in two cases (cases 8 and 22). Outcome and ejaculatory status All of the patients except for one (case 22) are alive with no evidence of disease during a mean follow-up of 25.8 months (range: 6 76 months). Twenty-two patients (84.6%) reported normal antegrade ejaculation within a mean period of 4.9 months after the nerve-sparing RPLND. Moreover, two patients (cases 7 and 23) fathered children 16 and 14 months after RPLND, respectively. Semen analysis was not routinely performed before or after RPLND. Discussion Retroperitoneal lymph node dissection plays an important role in the treatment of advanced testicular germ cell cancers. The objectives of postchemotherapy resection of a residual retroperitoneal mass and RPLND are to (i) document the presence or absence of viable cancer cells, and (ii) remove any teratoma. 12 Radical RPLND leads to disordered seminal emission and retrograde
5 Postchemotherapy nerve-sparing RPLND 543 ejaculation. Neuroanatomical studies created a basis for attempting to preserve normal ejaculation in patients with early stage testicular germ cell tumors without increasing the retroperitoneal recurrence rate by modifying the dissection template. 4 6 Nerve-sparing RPLND in selected patients with relatively small residual retroperitoneal masses after several courses of primary chemotherapy was first reported by Wahle et al. 8 Recently, nerve-sparing techniques have been extended to patients with advanced-stage disease who have relatively large residual retroperitoneal masses. Only a few cases of nerve-sparing postchemotherapy RPLND for relatively large residual retroperitoneal masses have been reported in the Japanese literature. 13 Solsona et al. 9 reported that 15 of 18 (83%) patients recovered ejaculatory function after RPLND, with recurrence in two patients (11.1%) during a mean follow-up of 28.1 months. In the other study, Coogan et al. 10 reported that emission and ejaculation were preserved in 62 of 81 patients (76.5%) after postchemotherapy RPLND, and tumor recurred in 7.4% of patients during a mean follow-up of 35.5 months. In both studies, the recurrence was at a site other than the retroperitoneum. In our study, ejaculatory function was preserved in 84.6% (22 of 26 patients) with only one retroperitoneal recurrence (case 22). This preservation rate (84.6%) of ejaculatory function is compatible with previous studies. 9,10 Coogan et al. 10 reported that bilateral nerve-sparing, or multilevel or right nerve-sparing improves the probability of preserving postoperative ejaculation. Wahle et al. 8 reported that a full left side dissection in the area below the inferior mesenteric artery increases the risk of distal sympathetic fiber injury. Nevertheless, there was no difference in the mean interval until the first antegrade ejaculation after RPLND between patients in whom the nerves were preserved bilaterally or unilaterally. Moreover, in one patient (case 24), only one nerve root was preserved on the right side, yet the patient was able to ejaculate normally within 7 months. These facts suggest that preservation of at least one of the lumbar splanchnic nerves is necessary and sufficient for normal ejaculation to occur. However, these nerves may be inadvertently damaged by mechanical manipulation or heat without the knowledge of the operators. Therefore, we try to preserve as many nerve roots as possible, even in patients with bilateral residual tumors. From the surgical point of view, it is easier to identify and preserve the right than the left lumbar splanchnic nerves. The right lumbar splanchnic nerves are easily identified as they run underneath the inferior vena cava. That is why the right-sided nerves usually are preserved in patients in whom unilateral preservation is done. Not only the lumbar splanchnic nerves, but also the superior hypogastric plexus are important for ejaculatory function. Therefore, great care must be taken to preserve this plexus when dissecting residual tumor located below the origin of the inferior mesenteric artery or around the aortic bifurcation. In terms of patient selection, a good candidate is one with a low tumor volume and unilateral disease after chemotherapy and, of course, who desires to remain fertile. Decreased fertility associated with testicular cancer and the risk of persistent azoospermia associated with chemotherapy must be considered when we select patients for nerve-sparing RPLND. 14 But, we do not have enough information about the patient s fertility status because we do not perform semen analyses routinely. In our study, all the patients request nerve-sparing procedure even after being informed that we do not have our own long-term results of this procedure in terms of cancer control. Testicular cancer often occurs in young patients. Chemotherapy-associated infertility and ejaculatory dysfunction after RPLND are serious problems for these men. According to Boyer and Raghaven s report 15 only 25% of patients remain persistently azoospermic. Nevertheless, ejaculatory dysfunction after RPLND compromises the quality of sexual life. Even if he is azoospermic, preservation of ejaculatory function may be desired and can improve the quality of a man s life. Therefore, nerve-sparing procedure can safely be extended to selected patients with metastatic testicular cancer. References 1 Donohue JP, Rowland RG. Complications of retroperitoneal node dissection. J. Urol. 1981; 125: Narayan P, Lange PH, Fraley EE. Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. J. Urol. 1982; 127: Arai Y, Kawakita M, Okada Y, Yoshida O. Sexuality and fertility in long-term survivors of testicular cancer. J. Clin. Oncol. 1997; 15: Jewett MA, Kang SP, Goldberg SD et al. Retroperitoneal lymphadenectomy for testis tumor with nervesparing for ejaculation. J. Urol. 1988; 139: Colleselli K, Poisel S, Schachter W, Bartsch G. Nervepreserving bilateral retroperitoneal lymphadenectomy: anatomical study and operative approach. J. Urol. 1990; 144: Donohue JP, Foster RS, Rowland RG, Bihrle R, Jones D, Geier G. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J. Urol. 1990; 144:
6 544 N Nonomura et al. 7 Lange PH, Chang WY, Fraley EE. Fertility issues in the treatment of nonseminomatous testicular tumors. Urol. Clin. North Am. 1987; 14: Wahle GR, Foster RS, Bihrle R, Rowland RG, Bennet RM, Donohue JP. Nerve-sparing retroperitoneal lymphadenectomy after primary chemotherapy for metastatic testicular carcinoma. J. Urol. 1994; 152: Solsona E, Iborra I, Ricos JV et al. Preservation of antegrade ejaculation in retroperitoneal lymphadenectomy due to residual masses after primary chemotherapy for testicular carcinoma. Eur. Urol. 1994; 25: Coogan CL, Hejase JH, Wahle GR et al. Nerve-sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J. Urol. 1996; 156: The Japanese Urological Association and the Japanese Pathological Society. General Rules for Clinical and Pathological Studies on Testicular Tumors, 2nd edn. Kanehara Shuppan, Tokyo, 1997 (in Japanese). 12 Skinner EC, Skinner DG. Surgery of testicular neoplasms. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds). Campbell s Urology, 7th edn. WB Saunders, Philadelphia, 1998: Arai Y, Ishitoya S, Kazutoshi O et al. Nerve-sparing retroperitoneal lymph node dissection for metastatic testicular cancer. Int. J. Urol. 1997; 4: Drasga RE, Einhorn LH, Williams SD, Patel DN, Stevens EE. Fertility after chemotherapy for testicular cancer. J. Clin. Oncol. 1983; 1: Boyer M, Raghaven D. Toxicity of treatment of germ cell tumors. Semin. Oncol. 1992; 19:
RETROPERITONEAL LYMPHADENECTOMY IN STAGING AND TREATMENT
~~~~ IFSTIS CANCtK 0094-0143/98 $8.00 +.00 RETROPERITONEAL LYMPHADENECTOMY IN STAGING AND TREATMENT The Development of Nerve-Sparing Techniques John P. Donohue, MD, and Richard S. Foster, MD Two decades
More informationResection of retroperitoneal residual mass after chemotherapy in patients with nonseminomatous testicular cancer
Turkish Journal of Cancer Vol.31/ No. 2/2001 Resection of retroperitoneal residual mass after chemotherapy in patients with nonseminomatous testicular cancer AHMET ÖZET 1, ALİ AYDIN YAVUZ 1, MURAT BEYZADEOĞLU
More informationModified and Bilateral Retroperitoneal Lymph Node Dissection for Testicular Cancer: Peri- and Postoperative Complications and Therapeutic Outcome
Modified and Bilateral Retroperitoneal Lymph Node Dissection for Testicular Cancer: Peri- and Postoperative Complications and Therapeutic Outcome Toshiaki Tanaka, Hiroshi Kitamura, Yasuharu Kunishima,
More informationHepatic Resection of Metastatic Testicular Carcinoma: A Further Update
Annals of Surgical Oncology, 6(7):640 644 Published by Lippincott Williams & Wilkins 1999 The Society of Surgical Oncology, Inc. Hepatic Resection of Metastatic Testicular Carcinoma: A Further Update Tara
More informationTesticular Malignancies /8/15
Collecting Cancer Data: Testis 2014-2015 NAACCR Webinar Series January 8, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationSignificance of simultaneous determination of serum human chorionic gonadotropin (hcg) and hcg-b in testicular tumor patients
International Journal of Urology (2000) 7, 218 223 Original Article Significance of simultaneous determination of serum human chorionic gonadotropin (hcg) and hcg-b in testicular tumor patients SENJI HOSHI,
More informationEjaculation in testicular cancer patients after postchemotherapy retroperitoneal lymph node dissection
British Journal of Cancer (999) 80(/2), 249 255 999 Cancer Research Campaign Article no. bjoc.998.0347 Ejaculation in testicular cancer patients after postchemotherapy retroperitoneal lymph node dissection
More informationRPLND: Tips and Tricks
RPLND: Tips and Tricks Andrew J. Stephenson, MD FACS FRCS(C) Director, Center for Urologic Oncology Glickman Urological & Kidney Institute Cleveland Clinic, Cleveland, OH RPLND: Keys to success Knowledge
More informationNICaN Testicular Germ Cell Tumours SACT protocols
Reference No: Title: Author(s) Ownership: Approval by: Systemic Anti-Cancer Therapy (SACT) Guidelines for Germ Cell Tumours Dr Audrey Fenton Consultant Medical Oncologist, Dr Vicky Coyle Consultant Medical
More informationViable Germ Cell Tumor at Postchemotherapy Retroperitoneal Lymph Node Dissection. Can We Predict Patients at Risk of Disease Progression?
2700 Viable Germ Cell Tumor at Postchemotherapy Retroperitoneal Lymph Node Dissection Can We Predict Patients at Risk of Disease Progression? Philippe E. Spiess, MD 1 Nizar M. Tannir, MD 2 Shi-Ming Tu,
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationThe Importance of One-Stage Median Stemotomy and Retroperitoneal Node Dissection in Disseminated Testicular Cancer
The Importance of One-Stage Median Stemotomy and Retroperitoneal Node Dissection in Disseminated Testicular Cancer Isidore Mandelbaum, M.D., Peter B. Yaw, M.D., Lawrence H. Einhorn, M.D., Stephen D. Williams,
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation in the Treatment of Germ File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_in_the_treatment_of_germ_cell_tumor
More informationFellow GU Lecture Series, Testicular Cancer. Asit Paul, MD, PhD 02/06/2018
Fellow GU Lecture Series, 2018 Testicular Cancer Asit Paul, MD, PhD 02/06/2018 Rare cancer worldwide, approximately 1% of all male cancers There is a large difference among ethnic/racial groups. Rates
More informationTESTICULAR CANCER Updated March 2016 by Dr. Safiya Karim (PGY-5 Medical Oncology Resident, University of Toronto)
TESTICULAR CANCER Updated March 2016 by Dr. Safiya Karim (PGY-5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Aaron Hansen (Staff Medical Oncologist, University of Toronto) DISCLAIMER:
More informationTesticular germ cell tumors
Testicular germ cell tumors Introduction Most common solid tumor in young adult men with 3 6 new cases/100,000 men/year. They acc ount for 1.5% of male malignancies and 5% of urological tumors. Bilateral
More informationFellow GU Lecture Series, Testicular Cancer. Asit Paul, MD, PhD 02/06/2018
Fellow GU Lecture Series, 2018 Testicular Cancer Asit Paul, MD, PhD 02/06/2018 Rare cancer worldwide, approximately 1% of all male cancers There is a large difference among ethnic/racial groups. Rates
More informationEAU GUIDELINES ON TESTICULAR CANCER
EAU GUIDELINES ON TESTICULAR CANCER (Limited text update March 2018) P. Albers (Chair), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi, A. Horwich, M.P. Laguna (Vice-chair), N. Nicolai,
More informationLong-Term Outcome for Men With Teratoma Found at Postchemotherapy Retroperitoneal Lymph Node Dissection
Original Article Long-Term Outcome for Men With Teratoma Found at Postchemotherapy Retroperitoneal Lymph Node Dissection Robert S. Svatek, MD 1, Philippe E. Spiess, MD 2, Debasish Sundi, BS 1, Shi-ming
More informationCase Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult
Case Scenario 1 Discharge Summary A 31-year-old Brazilian male presented with a 6 month history of right-sided scrotal swelling. Backache was present for 2 months and a history of right epididymitis was
More informationEAU GUIDELINES ON TESTICULAR CANCER
EAU GUIDELINES ON TESTICULAR CANCER (Limited text update March 2015) P. Albers (Chair), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi, A. Horwich, M.P. Laguna, N. Nicolai, J. Oldenburg
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of laparoscopic retroperitoneal lymph node dissection for testicular cancer Introduction
More informationSTAGING AND FOLLOW-UP STRATEGIES
ATHENS 4-6 October 2018 European Society of Urogenital Radiology STAGING AND FOLLOW-UP STRATEGIES Ahmet Tuncay Turgut, MD Professor of Radiology Hacettepe University, Faculty of Medicine Ankara 2nd ESUR
More informationCollecting Cancer Data: Testis 2/3/11. Collecting Cancer Data: NAACCR Webinar Series 1. Agenda. Fabulous Prizes
Collecting Cancer Data: Testis February 3, 2011 NAACCR 2010-2011 Webinar Series Agenda Coding moment Race/Hispanic origin Overview Collaborative Stage Treatment Exercises Fabulous Prizes NAACCR 2010-2011
More informationQuiz 1. Assign Race 1, Race 2 and Spanish Hispanic Origin to the following scenarios.
Quiz 1 Assign Race 1, Race 2 and Spanish Hispanic Origin to the following scenarios. 1. 62 year old Brazilian female Race 1 Race 2 Spanish/Hispanic Origin 2. 43 year old Asian male born in Japan Race 1
More informationSURGICAL ANATOMY OF RETROPERITONEUM AND LYMPHADENECTOMY
SURGICAL ANATOMY OF RETROPERITONEUM AND LYMPHADENECTOMY P. De Iaco S.Orsola-Malpighi Hospital - Bologna Unit Oncological Gynecology PELVIC AND AORTIC LYMPH NODE METASTASIS IN EPITHELIEL OVARIAN CANCER
More informationGUIDELINES ON TESTICULAR CANCER
38 (Text updated March 2005) P. Albers (chairman), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, A. Horwich, O. Klepp, M.P. Laguna, G. Pizzocaro Introduction Compared with other types of cancer
More informationPostchemotherapy Laparoscopic Retroperitoneal Lymph Node Dissection for Low-volume, Stage II, Nonseminomatous Germ Cell Tumor: First 100 Patients
EUROPEAN UROLOGY 63 (2013) 1013 1017 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Testis Cancer Editorial by Siamak Daneshmand and Inderbir S. Gill on
More informationTesticular Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version December 8, NCCN.org.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 2.2017 December 8, 2016 NCCN.org Continue Version 2.2017, 12/08/16 National Comprehensive Cancer Network, Inc. 2016, All rights
More informationTestis. Protocol applies to all malignant germ cell and malignant sex cord-stromal tumors of the testis, exclusive of paratesticular malignancies.
Testis Protocol applies to all malignant germ cell and malignant sex cord-stromal tumors of the testis, exclusive of paratesticular malignancies. Protocol revision date: January 2005 Based on AJCC/UICC
More informationCitation for published version (APA): Lutke Holzik, M. F. (2007). Genetic predisposition to testicular cancer s.n.
University of Groningen Genetic predisposition to testicular cancer Lutke Holzik, Martijn Frederik IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationEAU GUIDELINES ON TESTICULAR CANCER
EU GUIDELINES ON TESTICULR CNCER (Limited text update March 2017) P. lbers (Chair), W. lbrecht, F. lgaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi,. Horwich, M.P. Laguna, N. Nicolai, J. Oldenburg Introduction
More informationGerm cell tumors (GCT) are uncommon neoplasms
ORIGINAL ARTICLES: GENERAL THORACIC Pulmonary Metastasectomy for Testicular Germ Cell Tumors: A 28-Year Experience David Liu, MD, Amir Abolhoda, MD, Michael E. Burt, MD, PhD, Nael Martini, MD, Manjit S.
More informationCase Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult
Case Scenario 1 Discharge Summary A 31-year-old Brazilian male presented with a 6 month history of right-sided scrotal swelling. Backache was present for 2 months and a history of right epididymitis was
More informationAggressive Slurgical Management of Testicular Carcinoma Metastatic to Lungs and Mediastinurn
Aggressive Slurgical Management of Testicular Carcinoma Metastatic to Lungs and Mediastinurn Isadore Mandelbaum, M.D., Stephen D. Williams, M.D., and Lawrence H. Einhorn, M.D. ABSTRACT During the past
More informationRobot-assisted laparoscopic retroperitoneal lymph node dissection for stage IIIb mixed germ cell testicular cancer after chemotherapy
Case Report pissn 2005-6737 eissn 2005-6745 Robot-assisted laparoscopic retroperitoneal lymph node dissection for stage IIIb mixed germ cell testicular cancer after chemotherapy Sang Hyub Lee, Dong Soo
More informationPatients and methods. Results
Journal of BUON 10: 195-200, 2005 2005 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Germ cell testicular tumors in clinical stage A and normal values of serum tumor markers post-orchiectomy:
More informationPopulations Interventions Comparators Outcomes Individuals: With previously untreated germ cell tumors
Hematopoietic Cell Transplantation in the Treatment of Germ Cell (80135) (Formerly Hematopoietic Stem Cell Transplantation in the Treatment of Germ Cell ) Medical Benefit Effective Date: 04/01/13 Next
More informationASYMPTOMATIC COMPLEX TESTICULAR NEOPLASIA ASSOCIATED WITH ORCHIEPIDIDYMITIS. CASE REPORT
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2017 vol. 121, no. 4 SURGERY CASE REPORTS ASYMPTOMATIC COMPLEX TESTICULAR NEOPLASIA ASSOCIATED WITH ORCHIEPIDIDYMITIS. CASE REPORT Ș. Iacob 1, R. Vrînceanu 2,3, B.
More informationCardiff MRCS OSCE Courses Testicular Cancer
Testicular Cancer Scenario: A 40-year-old male presents to the surgical out-patient clinic with a 6-8 week history of a painless lump in his left scrotum. He however complains of a dull ache in the scrotum
More informationTesticular Cancer: Questions and Answers. Testicular cancer is a disease in which cells become malignant (cancerous) in one or both testicles.
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Testicular Cancer: Questions
More informationLate recurrence of an embryonal carcinoma of the testis. Case report
Late recurrence of an embryonal carcinoma of the testis. Case report Luminita Gurguta 1 *, Mihai V. Marinca 1, 2 1 Medical Oncology Department, Regional Institute of Oncology, Iasi, Romania, 2 Department,
More informationExercise. Discharge Summary
Exercise Discharge Summary A 32-year-old Brazilian male presented with a 6 month history of right-sided scrotal swelling. Backache was present for 2 months and a history of right epididymitis was present
More informationESMO Consensus Empfehlungen 2017
ESMO Consensus Empfehlungen 2017 What s old, what s new, what s missing? Jörg Beyer, Klinik für Onkologie Offenlegung Interessenskonflikte 1. Anstellungsverhältnis oder Führungsposition Keine 2. Beratungs-
More informationTeratocarcinoma In A Young Boy- An Unusual Presentation
Human Journals Case Report November 2015 Vol.:2, Issue:1 All rights are reserved by Atia Zaka-ur-Rab et al. Teratocarcinoma In A Young Boy- An Unusual Presentation Keywords: Boy, Testicular Mass, Teratocarcinoma
More informationTitle Late recurrence of nonseminomatous successfully treated with intensity Author(s) Kita, Yuki; Imamura, Masaaki; Mizow Yoshiki; Yoshimura, Koji; Hiraoka, Citation Japanese journal of clinical oncolo
More informationPoor-prognostic advanced Germ Cell Tumors
14-10-16 Poor-prognostic advanced Germ Cell Tumors Karim Fizazi, MD, PhD Institut Gustave Roussy, France Metastatic GCT: Prognosis (IGCCC) Good prognosis Intermediate prognosis Poor prognosis J Clin Oncol
More informationUncommon secondary tumour of the stomach
Uncommon secondary tumour of the stomach B. Bancel, Hôpital CROIX ROUSSE LYON Bucharest Nov 2013 Case report 33-year old man Profound mental retardation and motor disturbances (sequelae of neonatal meningeal
More informationGerm Cell Tumors. Karim Fizazi, MD, PhD Institut Gustave Roussy, France
Germ Cell Tumors Karim Fizazi, MD, PhD Institut Gustave Roussy, France Surveillance for stage I GCT NSGCT A 26 year-old patient had a orchiectomy revealing embryonal carcinoma (40%), seminoma (40%) and
More informationNonseminomatous germ cell tumors (NSGCTs) of testicular origin are the
General Thoracic Surgery Kesler et al Surgical salvage therapy for malignant intrathoracic metastases from nonseminomatous germ cell cancer of testicular origin: Analysis of a single-institution experience
More informationTwelve Years of Experience in the Management of Testicular Germ Cell Tumors at a Referral Center in Portugal
Elmer Press Original Article Twelve Years of Experience in the Management of Testicular Germ Cell Tumors at a Referral Center in Portugal Diana Valadares a, c, Filipe Nery a, Franklim Marques a, b Abstract
More informationSurveillance Alone Versus Radiotherapy After Orchiectomy for Clinical Stage I Nonseminomatous Testicular Cancer
Surveillance Alone Versus Radiotherapy After Orchiectomy for Clinical Stage I Nonseminomatous Testicular Cancer By Mikael Rorth, Grethe Krag Jacobsen, Hans von der Maase, Ebbe Lindegdrd Madsen, Ole Steen
More informationBilateral Testicular Germ Cell Tumors
1228 Bilateral Testicular Germ Cell Tumors Twenty-Year Experience at M. D. Anderson Cancer Center Mingxin Che, M.D., Ph.D. 1 Pheroze Tamboli, M.D. 1 Jae Y. Ro, M.D., Ph.D. 1 Dong Soo Park, M.D. 2 Jung
More informationRunning Title: Utility of HCG Washout in Cervical LND FNA
AACE Clinical Case Reports Rapid Electronic Articles in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited,
More informationTesticular Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2014 NCCN.org Continue Version 1.2014, 12/13/13 National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN
More informationMixed Germ Cell Testis Tumor Presenting with Massive Lung Metastasis
International Archives of Medical Research Volume 10, No.1, pp.21-26, 2018. CASE REPORT RESEARCH Mixed Germ Cell Testis Tumor Presenting with Massive Lung Metastasis Zuhat Urakci 1, Senar Ebinc 1, Ogur
More informationNote: The cause of testicular neoplasms remains unknown
- In the 15- to 34-year-old age group, they are the most common tumors of men. - Tumors of the testis are a heterogeneous group of neoplasms that include: I. Germ cell tumors : 95%; all are malignant.
More information-The cause of testicular neoplasms remains unknown
- In the 15- to 34-year-old age group, they are the most common tumors of men. - include: I. Germ cell tumors : (95%); all are malignant. II. Sex cord-stromal tumors: from Sertoli or Leydig cells; usually
More informationAnalysis of the prognosis of patients with testicular seminoma
ONCOLOGY LETTERS 11: 1361-1366, 2016 Analysis of the prognosis of patients with testicular seminoma WEI DONG 1, WANG GANG 1, MIAOMIAO LIU 2 and HONGZHEN ZHANG 2 1 Department of Urology; 2 Department of
More informationANZUP SURVEILLANCE RECOMMENDATIONS FOR METASTATIC TESTICULAR CANCER POST-CHEMOTHERAPY
ANZUP SURVEILLANCE RECOMMENDATIONS FOR METASTATIC TESTICULAR CANCER POST-CHEMOTHERAPY Note: These surveillance recommendations are provided as recommendations only. Clinicians should take into account
More informationThe growing teratoma syndrome in primary mediastinal nonseminomatous germ cell tumors: Criteria based on current practice
General Thoracic Surgery Kesler et al The growing teratoma syndrome in primary mediastinal nonseminomatous germ cell tumors: Criteria based on current practice Kenneth A. Kesler, MD, a Jay B. Patel, MD,
More informationRetroperitoneal schwannoma mimickin metastasis of seminoma. Author(s) Masahumi; Shimoji, Toshio; Miyake, Citation 泌尿器科紀要 (1991), 37(3):
Title Retroperitoneal schwannoma mimickin metastasis of seminoma Author(s) Takashi, Munehisa; Sakata, Takao; Z Masahumi; Shimoji, Toshio; Miyake, Citation 泌尿器科紀要 (1991), 37(3): 255-258 Issue Date 1991-03
More informationLong-term results after inferior vena caval resection during retroperitoneal lymphadenectomy for metastatic germ cell cancer
Long-term results after inferior vena caval resection during retroperitoneal lymphadenectomy for metastatic germ cell cancer Stephen D. W. Beck, MD, Stephen G. Lalka, MD, and John P. Donohue, MD, Indianapolis,
More informationTesticular cancer and other germ cell tumours. London Cancer Jonathan Shamash
Testicular cancer and other germ cell tumours London Cancer 2018 Jonathan Shamash Background Testicular germ cell tumours are the commonest cancers of young men Overall they are curable but long term side
More informationNerve-preserving aortoiliac reconstruction surgery: Anatomical study and surgical approach
CLINICAL RESEARCH STUDIES Nerve-preserving aortoiliac reconstruction surgery: Anatomical study and surgical approach Jan van Schaik, a Jary M. van Baalen, MD, PhD, b Michel J. T. Visser, MD, PhD, b and
More informationPostchemotherapy Retroperitoneal Lymph Node Dissection in Advanced Testicular Cancer: Radical or Modified Template Resection
european urology 55 (2009) 217 226 available at www.sciencedirect.com journal homepage: www.europeanurology.com Testis Cancer Postchemotherapy Retroperitoneal Lymph Node Dissection in Advanced Testicular
More informationNonseminomatous Germ Cell Tumors Urinary Incontinence
UROLOGY BOARD REVIEW MANUAL PUBLISHING STAFF PRESIDENT, GROUP PUBLISHER Bruce M. White EXECUTIVE EDITOR Debra Dreger ASSISTANT EDITOR Laurie Garrison EDITORIAL ASSISTANT A.C. Arkles EXECUTIVE VICE PRESIDENT
More informationTesticular Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version November 2, NCCN.org.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2017 November 2, 2016 NCCN.org Continue Panel Members * Timothy Gilligan, MD/Chair Case Comprehensive Cancer Center/ University
More informationWhat is Testicular cancer?
Testicular Cancer What is Testicular cancer? Testicular cancer is a disease in which cancer cells form in the tissues of one or both testicles. The testicles are 2 egg-shaped glands located inside the
More informationProf. Dr. med. Beata BODE-LESNIEWSKA Institute of Pathology and Molecular Pathology University Hospital; Zurich
Prof. Dr. med. Beata BODE-LESNIEWSKA Institute of Pathology and Molecular Pathology University Hospital; Zurich 32 year old man 2 months history of growing left supraclavicular lymph nodes Antibiotic treatment
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM GERM CELL TUMOURS CNS Site Group Germ Cell Tumours Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Testicular Cancer
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 2.2016 NCCN.org Continue Panel Members * Robert J. Motzer, MD/Chair Þ Memorial Sloan Kettering Cancer Center Steven L. Hancock,
More informationReceived February 1, 2007
NEOPLASMA 54, 5, 2007 437 Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only D. ONDRUS
More informationRepeat Retroperitoneal Lymphadenectomy in Advanced Testicular Cancer
European Urology European Urology 47 (2005) 64 71 Repeat Retroperitoneal Lymphadenectomy in Advanced Testicular Cancer Axel Heidenreich a,b, *, Carsten Ohlmann a,b, Axel Hegele b,jörg Beyer c a Division
More informationGUIDELINES ON TESTICULAR CANCER
European Association of Urology GUIDELINES ON TESTICULAR CANCER P. Albers (chairman), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, A. Horwich, O. Klepp, M.P. Laguna, G. Pizzocaro UPDATE MARCH
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationTesticular Cancer. J. Richard Auman, MD. James J. Stark, MD. Jerry Singer, MD. September 19, 2008
Testicular Cancer J. Richard Auman, MD James J. Stark, MD Jerry Singer, MD September 19, 2008 Testicular Cancer From mystery to far-advanced disease: a remarkable case Case Presentation. 23 y. o. male
More informationR the first site of metastasis for germinal DISTRIBUTION OF RETROPERITONEAL LYMPH GERMINAL TUMORS NODE METASTASES IN TESTICULAR
DISTRIBUTION OF RETROPERITONEAL LYMPH NODE METASTASES IN TESTICULAR GERMINAL TUMORS RISWAMAY RAY, MD, STEVEN I. HAJDU, WILLET F. WHITMORE, JR, MD MD, AND A detailed analysis of the retroperitoneal lymph
More informationRadical lymph node resection of the retroperitoneal area for left-sided colon cancer
Langenbecks Arch Surg (2007) 392:155 160 DOI 10.1007/s00423-006-0143-4 ORIGINAL ARTICLE Radical lymph node resection of the retroperitoneal area for left-sided colon cancer Antonios-Apostolos K. Tentes
More informationGerm cell tumours local perspectives on a curable cancer
REVIEW Germ cell tumours local perspectives on a curable cancer ATC Chan, MMC Cheung, WH Lau, PJ Johnson Germ cell tumours are among the most curable solid cancers and have become a model for the multimodality
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.8.3267 Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection for Germ Cell Testicular Cancer RESEARCH ARTICLE Comparative Effectiveness of Risk-adapted
More informationMetastasis of Testicular Carcinoma in The Inguinal Region
CASE REPORT Agus Rizal AH Hamid, Rainy Umbas Department of Urology, Faculty of Medicine, University of Indonesia - dr. Cipto Mangunkusumo Hospital. Jl. Diponegoro no. 71, Jakarta Pusat. Correspondence
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationThe Management of Nonseminomatous Testicular Cancer
Articles TheScientificWorldJOURNAL (2004) 4 (S1), 316 329 ISSN 1537-744X; DOI 10.1100/tsw.2004.85 The Management of Nonseminomatous Testicular Cancer Graeme S. Steele, MBBCh, FCS and Jerome P. Richie,
More informationIntroduction. pissn , eissn Open Access. Case Report
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2015;47(4):931-936 Case Report http://dx.doi.org/10.4143/crt.2014.049 Open Access Conventional Cisplatin-Based Combination Chemotherapy Is Effective in
More informationSaudi Oncology Society and Saudi Urology Association combined clinical management guidelines for testicular germ cell tumors
Review Article Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for testicular germ cell tumors Mohammed Alotaibi, Ahmad Saadeddin 1, Shouki Bazarbashi 2, Sultan
More informationThe anterior mediastinum represents the second most
Technique of Mediastinal Germ Cell Tumor Resection Kenneth A. Kesler, MD The anterior mediastinum represents the second most common site of germ cell tumor origin. Nonseminomatous germ cell cancers not
More informationManagement of Testicular Cancer
Management of Testicular Cancer Christian Kollmannsberger MD FRCPC Clinical Professor Div. of Medical Oncology BC Cancer - Vancouver Cancer Centre Dept. of Medicine, University of British Columbia Associate
More informationeditoriale Optimal lymph node dissection for T3-T4 lower rectal cancer, the so-called high risk group: the Japanese experience Introduction
G Chir Vol. 30 - n. 10 - pp. 393-399 Ottobre 2009 editoriale Optimal lymph node dissection for T3-T4 lower rectal cancer, the so-called high risk group: the Japanese experience M. YASUNO Introduction The
More informationGERM-CELL TUMOURS. ESMO Preceptorship on Adolescents and Young Adults with cancer Lugano, May 2018
ESMO Preceptorship on Adolescents and Young Adults with cancer Lugano, 11-12 May 2018 GERM-CELL TUMOURS Giannis Mountzios MSc, PhD Medical Oncology University of Athens School of Medicine Athens, Greece
More informationReceived February 17, 2014 / Received April 9, 2014
Neoplasma 62, 1, 2015 159 doi:10.4149/neo_2015_001 Management of patients with clinical stage I nonseminomatous germ cell testicular cancer: Active surveillance versus adjuvant chemotherapy single-centre
More informationBoston University School of Medicine, Boston University Medical Center, and Beth Israel Hospital and Boston NF, Boston, Massachusetts
l FERTILITY AND STERILITY Copyright @ 1995 American Society for Reproductive Medicine Vol. 64, No.6, December 1995 Printed on acid-free paper in U. S. A. The achievement of pregnancies using assisted reproductive
More informationMULTIDISCIPLINARY GENITOURINARY ONCOLOGY COURSE
MULTIDISCIPLINARY GENITOURINARY ONCOLOGY COURSE Case 2 Testicular Cancer Nuno Sineiro Vau Medical Oncologist Champalimaud Foundation, Lisbon October 2017 Male, 36 year-old, sales manager. Past medical
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationPrimary mediastinal nonseminomatous germ cell tumors
ORIGINAL ARTICLE Resection of Primary Mediastinal Non-Seminomatous Germ Cell Tumors A 28-Year Experience at Memorial Sloan-Kettering Cancer Center Inderpal S. Sarkaria, MD,* Manjit S. Bains, MD,* Shelly
More informationbleomycin, etoposide and cis-platin (BEP)
Br. J. Cancer (1983), 47, 613-619 The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP) M.J. Peckham, A. Barrett, K.H. Liew, A. Horwich, B. Robinson, H.J.
More informationKaroline Nowillo, MD. February 1, 2008
Case Presentation Karoline Nowillo, MD SUNY Downstate t February 1, 2008 Case Presentation Chief complaint enlarging goiter x 8 months History of present illness shortness of breath, heaviness in chest
More informationPage 1 of 17 TABLE OF CONTENTS
Page 1 of 17 TABLE OF CONTENTS Suspicious Testicular Cancer. Page 2 nseminomatous Germ Cell Tumor (NSGCT): workup and clinical stage Page 3 Seminoma: workup and clinical stage... Page 4 Clinical Stage
More informationMultimodality Treatment of Germ Cell Tumors of the Mediastinum
Multimodality Treatment of Germ Cell Tumors of the Mediastinum Kenneth A. Kesler MD a, *,LawrenceH.Einhorn,MD b KEYWORDS Germ cell tumors Mediastinal tumors Nonseminomatous germ cell cancer Thoracic surgery
More information